Canadian Cancer Trials Group Bulletins

Group Administrators Office

Dr. Laura Dawson Awarded CCSRI QoL Grant

We are very pleased to inform you that Dr. Laura Dawson, radiation oncologist at the Princess Margaret Cancer Centre, has been awarded $299,916 from the CCSRI Quality of Life grant panel for her phase III trial looking at palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases. Co-investigators include Drs Jolie Ringash, Rebecca Wong, Camilla Zimmermann and Derek Jonker. Dr. Chris O'Callaghan is the Canadian Cancer Trials Group Central Office Senior Investigator and Dr. Dongsheng Tu is the trial biostatistician.

The primary objective of the study is to determine if a single 8 Gy dose of RT increases the proportion of patients with pain or discomfort from HCC or liver metastases who report an improvement by ≥ 2 points in pain "intensity on average" on the brief pain inventory (BPI) from baseline to 1 month relative to those managed with BSC alone. Secondary objectives are to compare CTCAEv4.0 toxicity and 3-month survival in patients treated with RT versus BSC alone, and to compare at 1 and 3 months the proportion of patients with a clinically significant improvement in all BPI scores, in QOL (FACT hepatobiliary and other subscales), and a 25% reduction in analgesia use at 1 month.

The trial will be conducted by the Canadian Cancer Trials Group. We hope to enroll a total of 60 patients from 11 Canadian centres.

Congratulations to Laura!